Project Grant R01CA315233
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $882K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
University City, MO 63130, USA
Similar Awards
- The National Cancer Institute awarded The Washington University $155,500 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize the direct and indirect costs of fertility preservation options for adolescent and young adult cancer survivors, including out-of-pocket fees, transportation, and time off work for parents and caregivers. The research addresses financial hardship among adolescent and young adult cancer survivors, examining how cost...
- The National Cancer Institute awarded The Washington University $160,093 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate perceptions and informational needs regarding prostate cancer screening among screening-eligible men, with particular attention to racial disparities. The research addresses how men perceive the harms and benefits of prostate-specific antigen (PSA)-based screening, especially in the context of risk-stratified screening...
- The National Cancer Institute awarded The Washington University $425,088 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to evaluate the delivery and quality of lung cancer care among older adults enrolled in Medicare Advantage versus traditional Medicare. The research examines disparities in lung cancer screening, diagnosis, treatment patterns, and clinical outcomes across these two insurance programs. The project compares guideline-concordant treatment...
- The National Cancer Institute awarded The Washington University $659,087 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research targeting the NRF2 oxidative stress response pathway to sensitize head and neck squamous cell carcinoma (HNSCC) to immune checkpoint inhibitors. The research develops mechanistic understanding of how NRF2 pathway activation drives immune exclusion and resistance to anti-PD1 immunotherapy in HNSCC, which accounts for the sixth...
- The National Cancer Institute awarded The Washington University $399,829 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to mechanistically characterize a novel dendritic cell-based immunotherapy for solid tumors. The project will investigate how engineered dendritic cells expressing a B7H3-specific chimeric antigen receptor fused to toll-like receptor 4 signaling domains can overcome tumor immune tolerance by efficiently capturing tumor antigens and cross-priming...
- The National Institutes of Health National Cancer Institute awarded The Washington University $399,829 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to conduct rational design of next-generation engineered T cells for enhanced cancer immunotherapy. The research addresses limited persistence of engineered T cells in cancer treatment by harnessing 4-1BB (CD137/TNFRSF9), a co-stimulatory molecule, through structure-informed protein design. Current 4-1BB chimeric...
- The National Cancer Institute awarded The Washington University $637,394 on August 5, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop positron emission tomography imaging using a radiotracer (64Cu-DOTA-ECL1I) that quantifies C-C motif chemokine receptor 2 (CCR2) expression in head and neck squamous cell carcinoma patients. The project will establish CCR2-PET as a prognostic biomarker to predict tumor activity, disease recurrence, and response to...
- The National Cancer Institute awarded Washington University $667,491 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct a multi-center investigation integrating positron emission tomography imaging and circulating tumor DNA analysis to predict response to PARP inhibitor therapy in metastatic castration-resistant prostate cancer patients. The recipient will lead a three-site imaging trial at Washington University School of Medicine, MD...
- The National Institutes of Health National Cancer Institute awarded The Washington University $645,185 under the Cancer Treatment Research program (CFDA 93.395) on May 15, 2026, to develop and test a combination immunotherapy approach for glioblastoma. The recipient will conduct research on an "expand and pull" strategy combining long-acting interleukin-7 (IL-7) with oncolytic virus therapy to expand peripheral CD8+ T cells and recruit them into the glioblastoma tumor microenvironment....
- The National Cancer Institute awarded The Washington University $623,616 on July 10, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support development of PET imaging methods for detecting and quantifying CD163+ tumor-associated macrophages in head and neck cancer. The research addresses the role of tumor-associated macrophages (TAMs) in the tumor microenvironment, which coordinate angiogenesis, extracellular matrix remodeling, cancer cell proliferation,...